Compare · GLP-1 agonist
CagriSema vs Survodutide
Both are glp-1 agonist compounds. Here's how they line up on the evidence — graded the same way.
| CagriSema | Survodutide | |
|---|---|---|
| Evidence | Strong human | Preliminary human |
| Class | GLP-1 agonist | GLP-1 agonist |
| Summary | An investigational once-weekly fixed combination of cagrilintide (an amylin analog) plus semaglutide (a GLP-1 drug) with large peer-reviewed Phase 3 weight-loss data, but no approval yet and a failed head-to-head against tirzepatide. | An investigational GLP-1/glucagon dual agonist with solid placebo-controlled Phase 2 trials and one positive Phase 3 topline, but no approval and no peer-reviewed Phase 3 data. |
| Full profile → | Full profile → |
CagriSema
CagriSema is one of the most heavily studied combination products in the obesity-drug pipeline, and also a useful case study in why "strong trial data" and "proven, approved, and better than the alternatives" are not the same thing. It is a once-weekly injectable that fixes two peptides into a…
Survodutide
Survodutide (development code BI 456906) is an investigational injectable drug being studied for obesity, fatty-liver disease, and type 2 diabetes. It has a stronger human evidence base than most peptides sold online, including several well-run placebo-controlled trials and one positive Phase 3…